Physician profile
Sean Javaheri
NPI 1982677605
$13,115.53
in general payments reported to CMS, 2019-2025
28 companies · $638 in 2025
The $638 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $907 · 2020: $578 · 2021: $7,662 · 2022: $2,194 · 2023: $535 · 2024: $602 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,774.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $9,104.79 | 2019-2025 | Lifevest |
| Abiomed | $1,057.62 | 2019-2025 | Impella |
| Medtronic, INC. | $636.92 | 2021-2025 | Azure Xt Dr Mri Surescan, Cobalt Dr Mri Surescan, Onyx Frontier |
| Medtronic Vascular, INC. | $608.07 | 2019-2020 | |
| Abbott Laboratories | $287.09 | 2019-2024 | Coroflow |
| Inari Medical, INC. | $241.60 | 2020-2021 | |
| Shockwave Medical, INC | $189.88 | 2025 | |
| Stryker Corporation | $169.79 | 2025 | Flowtriever, Artix Mt |
| Novartis Pharmaceuticals Corporation | $135.70 | 2019-2024 | |
| Astrazeneca Pharmaceuticals Lp | $132.95 | 2019-2024 | Farxiga |
| W. L. Gore & Associates, INC. | $80.28 | 2019-2024 | Gore Cardioform Septal Occluder |
| Janssen Pharmaceuticals, INC | $67.35 | 2019-2020 | |
| Amgen INC. | $65.59 | 2020-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $39.84 | 2024-2025 | Camzyos |
| Pfizer INC. | $38.20 | 2020-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $34.84 | 2019-2021 | |
| Philips North America LLC | $29.72 | 2020-2022 | |
| Novo Nordisk INC | $28.24 | 2025 | Wegovy |
| Esperion Therapeutics, INC. | $24.56 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.23 | 2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $22.87 | 2024 | Opsumit |
| Scpharmaceuticals INC. | $19.39 | 2025 | |
| Penumbra, INC. | $18.00 | 2023 | Indigo System |
| Asahi Intecc USA, INC. | $16.58 | 2022 | |
| Biotronik INC. | $15.50 | 2023 | Orsiro Mission, Nhancer Rx |
| Astellas Pharma US INC | $14.75 | 2020 | |
| Cardiovascular Systems INC. | $12.18 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Javaheri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.